Evidence map›Paper›PMID 39386664›Full record

ArticlebioRxiv : the preprint server for biology2024

Distinct roles of the two BRCA2 DNA binding domains in DNA damage repair and replication fork preservation.

Francisco Neal, Wenjing Li, Mollie E Uhrig, Neelam Sharma, Shahrez Syed, Sandeep Burma, Robert Hromas, Alexander Mazin, Eloise Dray, David Libich and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Novel De NovoInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Wenjing Li
Mollie E Uhrig
Neelam Sharma
Shahrez Syed
Sandeep Burma
Elizabeth WasmuthORCID 0000-0003-1474-4935
Claus S SørensenORCID 0000-0001-6022-9710

Funding

Genome Maintenance via the BRCA-RAD54 Axis.R01GM141091 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ZHAO, WEIXING WILSON · 2021 to 2025
$1.8M
Understanding post translational modifiers in DNA damage repairR21ES035997 · NIEHS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DRAY, ELOISE · 2024 to 2025
$426k
NIEHS NIH HHS R21 ES035997NIGMS NIH HHS R01 GM141091
6 · The paper itself

Abstract

Homologous recombination (HR) is a highly conserved tool for the removal of DNA double-strand breaks (DSBs) and the preservation of stalled and damaged DNA replication forks. Successful completion of HR requires the tumor suppressor BRCA2. Germline mutations in BRCA2 lead to familial breast, ovarian, and other cancers, underscoring the importance of this protein for maintaining genome stability. BRCA2 harbors two distinct DNA binding domains, one that possesses three oligonucleotide/oligosaccharide binding (OB) folds (known as the OB-DBD), and with the other residing in the C-terminal recombinase binding domain (termed the CTRB-DBD) encoded by the last gene exon. Here, we employ a combination of genetic, biochemical, and cellular approaches to delineate contributions of these two DNA binding domains toward HR and the maintenance of stressed DNA replication forks. We show that OB-DBD and CTRB-DBD confer ssDNA and dsDNA binding capabilities to BRCA2, respectively, and that BRCA2 variants mutated in either DNA binding domain are impaired in the ability to load the recombinase RAD51 onto ssDNA pre-occupied by RPA. While the CTRB-DBD mutant is modestly affected for HR, it exhibits a strong defect in the protection of stressed replication forks. In contrast, the OB-DBD is indispensable for both BRCA2 functions. Our study thus defines the unique contributions of the two BRCA2 DNA binding domains in genome maintenance.

Identifiers

PMID39386664
PMCPMC11463483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.